Prostate Cancer: Why Waiting for Symptoms Isn’t a Plan

It’s November, and someone at work is growing a mustache for Movember. Between jokes, the question comes up: “So, have you had your prostate checked?” You’re 52. You pee without trouble, sleep through the night, and feel strong. You think what almost anyone would think: if something were wrong, I’d know by now.

It’s a sensible idea, and with the prostate it often fails. The useful question isn’t “Do I have symptoms?” It’s “At my age, with my family history, is it worth talking about a blood test called PSA?” The answer isn’t the same for every man. That’s why it helps to know what you stand to gain, what you risk, and what it costs in time, money, and peace of mind before you decide.

The essentials in 30 seconds

• Early prostate cancer almost never causes symptoms. Trouble urinating usually comes from benign prostate enlargement.
• Early detection (screening) starts with a blood test, the PSA, not with a rectal exam.
• The benefit is real but modest: fewer deaths and less advanced cancer. The price is false alarms and diagnoses of tumors that would never have caused harm.
• The conversation usually starts around age 50, and at 45 or earlier if you are Black or of African ancestry, or if your father or a brother had prostate cancer.
• A high PSA is not a diagnosis. First it gets repeated. After that, MRI and active surveillance prevent many unnecessary biopsies and treatments.

Why symptoms show up late

In the United States, one in eight men will be diagnosed with prostate cancer during his lifetime, and it is the most common cancer among American men. Worldwide, the GLOBOCAN estimates counted about 1.5 million new cases and nearly 400,000 deaths in 2022. It is also the most commonly diagnosed cancer in men across Latin America and the Caribbean, and the Caribbean has some of the highest death rates in the world. For many of our families, this is not a distant statistic.

A 2025 review in JAMA puts it plainly: while the tumor is confined to the prostate, it rarely causes symptoms. There’s an anatomical reason. About 70% of tumors grow in the outer zone of the gland, away from the channel that carries urine. A weak stream or getting up at night usually comes from benign enlargement, which happens in a different zone. Even so, an analysis in BMC Medicine cites a survey in which 86% of people linked this cancer to symptoms and only 1% knew it can be silent.

Stage at diagnosis changes the picture. According to the American Cancer Society, five-year survival approaches 100% when the cancer is local or regional and drops to 37% once it has spread to distant sites. And late diagnosis is rising: in the U.S., distant-stage cases have grown about 6% a year in men ages 55 to 69, according to Prostate Cancer Statistics, 2025. The same report shows that Hispanic men are less likely than White and Black men to be diagnosed while the cancer is still localized (64%–67% versus 71%–72%).

Access is part of the story. In the Hispanic Community Health Study/Study of Latinos, fewer than half of Latino men ages 55 to 69 had ever had a PSA test. Men of Cuban background were less likely to have been tested than men of Mexican background, and not having a regular primary care doctor was one of the factors tied to going untested.

What the studies show about PSA

The best evidence comes from the European ERSPC trial, which followed more than 160,000 men for 23 years and was published in The New England Journal of Medicine in 2025. Inviting men to PSA testing lowered deaths from prostate cancer by 13%: one death prevented for every 456 men invited. The 2026 Cochrane review translates it this way: out of every 1,000 men, about 16 die of this cancer without screening and about 14 with it. Screening has not been shown to change deaths from all causes.

That benefit has costs. In the same trial, 16% of PSA tests came back elevated, and only 24% of the biopsies that followed found cancer. There were also 27 extra diagnoses for every 1,000 men, many of them low-risk tumors. The U.S. Preventive Services Task Force (USPSTF) estimates that 20% to 50% of cancers found through screening would never have caused problems. Treating them carries real effects: after surgery, about 15% of men have urine leakage at one year, and 20% to 60% have erectile dysfunction, according to the JAMA review.

What has changed is how a high result gets handled. The AUA/SUO guideline notes that 25% to 40% of elevated PSA results return to normal when repeated. A meta-analysis in JAMA Oncology found that with an MRI before biopsy, it took 2 biopsies to find one significant cancer; without it, 6. And the British ProtecT trial showed that 15 years later, about 97% of men with localized cancer had not died of it, whether they had surgery, radiation, or monitoring. Monitoring did bring more spread of the cancer (9% versus 5%), but one in four of those men still had not needed any treatment.

Where the guidelines agree and where they don’t

• The American Cancer Society (2026) recommends a PSA every two years from ages 50 to 69 for men at average risk. It moves the start to 45 for Black men (yearly) and for men whose father or brother had the disease (yearly or every two years, depending on the details). From 70 to 74 the decision is individual; at 75, screening stops.
• The AUA/SUO suggests a baseline PSA between 45 and 50, starting at 40 to 45 for men at higher risk, and repeating it every two to four years.
• The USPSTF (2018, now being updated) calls for an individual decision from 55 to 69 and recommends against screening from age 70.
• The European EAU guideline (2026) advises a risk-based approach starting at 50. Its recent versions move that to 45 for men of African descent or with a family history, and to 40 for men with a BRCA2 mutation.

They agree on what matters most: the decision should be an informed one, and screening loses its value at older ages or when another serious illness limits life expectancy. Most countries in Latin America and Europe still have no organized program that calls you in, and in the United States no one will schedule this for you either. The conversation starts when you or your doctor bring it up.

How I read it as a family doctor

So far, the data. What follows is my own interpretation.

I don’t think PSA deserves blind faith or outright rejection. For a healthy man between 50 and 69, or from 45 if his risk is higher, I find it reasonable to have the conversation and, if he chooses, to get a PSA every two years. I attach one condition: agree beforehand on what we’ll do if it comes back high. Repeat it, order an MRI, and watch rather than treat when a tumor is low-risk. Saying “I’d rather not test” after understanding the numbers is also a valid decision.

What I don’t recommend is treating the absence of symptoms as a plan, or getting the test without having talked about what comes next.

That’s where your family doctor matters. We know your history and your medications; finasteride and dutasteride, for example, cut PSA roughly in half. We know if you had a recent urinary infection. And we can put the steps in order so that one number doesn’t turn into a chain of tests.

What it means for you: benefits, risks, and burdens

What you may gain. A lower chance of dying of prostate cancer or of finding it after it has already spread. The gain is larger if your risk is high and you have many years ahead of you.

What you may risk. A false alarm, weeks of worry, a biopsy that could have been avoided, or the diagnosis of a slow tumor that turns you into a patient without need.

What it costs in practice. A PSA is a blood draw that takes a few minutes. The rectal exam is not the first step; guidelines do not recommend it as a stand-alone test. If the result is high, expect a second blood draw and possibly an MRI, which costs more and isn’t available everywhere. Price and coverage vary by country and by insurance plan, so ask first. If you’re uninsured in the United States, community health centers charge on a sliding scale based on income. In Spain and much of Latin America, the way in is your local health center.

Five doable steps this week

1. Ask at home. Find out whether your father, brothers, or uncles had prostate cancer and at what age, and whether there is breast or ovarian cancer in the family. It’s one phone call.
2. Find your place. With your age and that history, see which guideline group fits you.
3. Book a visit with your family doctor and say it up front: “I want to talk about PSA.” If you don’t have a doctor, this is a good reason to find one.
4. Bring three questions. What is my risk? If it comes back high, what would we do first? How often would I repeat it?
5. If you decide to test, to be safe, avoid ejaculation and hard cycling for 24 to 48 hours beforehand, and mention your medications and any recent urinary infection.

When to call without waiting

This is no longer screening; it’s a reason to be seen soon: blood in your urine, being unable to urinate or to empty your bladder, and persistent bone pain in the back or hips, especially with weakness in the legs. Common urinary complaints, such as a weak stream or getting up at night, are almost always benign and treatable. They deserve an appointment, not panic.

What changes once you’ve had the talk

If you have the conversation this month, you walk out of the visit with three concrete things: you know your risk group, you have a date for your next check, and you have a plan if the number goes up. Your prostate stops being a question that comes back every November and becomes something with a schedule. And the day your brother, your son, or the coworker with the mustache asks, you’ll be able to tell him how you decided.

---

Key readings

1. Hoffman, Richard M., et al. “American Cancer Society Guideline for the Early Detection of Prostate Cancer, 2026.” CA: A Cancer Journal for Clinicians, 2026. PubMed.
2. American Urological Association and Society of Urologic Oncology. “Early Detection of Prostate Cancer.” 2026. auanet.org.
3. US Preventive Services Task Force. “Screening for Prostate Cancer: Recommendation Statement.” JAMA, 2018.
4. Cornford, Philip, et al. “EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2026 Update. Part I.” European Urology, 2026. PubMed.
5. Roobol, Monique J., et al. “European Study of Prostate Cancer Screening — 23-Year Follow-up.” The New England Journal of Medicine, 2025. PubMed.
6. Raychaudhuri, Ruben, et al. “Prostate Cancer: A Review.” JAMA, 2025.

Other scientific sources

7. Franco, Juan V. A., et al. “Prostate-Specific Antigen (PSA) Test for Prostate Cancer Screening.” Cochrane Database of Systematic Reviews, 2026.
8. Hamdy, Freddie C., et al. “Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.” The New England Journal of Medicine, 2023.
9. Fazekas, Tamás, et al. “Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis.” JAMA Oncology, 2024.
10. Kratzer, Tyler B., et al. “Prostate Cancer Statistics, 2025.” CA: A Cancer Journal for Clinicians, 2025. PubMed.
11. Noriega Esquives, Blanca S., et al. “Factors Associated With Prostate Cancer Screening Among Hispanic Men: Results From the Hispanic Community Health Study/Study of Latinos.” Cancer, 2025. PubMed.
12. Wagle, Nikita S., et al. “Cancer Treatment and Survivorship Statistics, 2025.” CA: A Cancer Journal for Clinicians, 2025.
13. Bray, Freddie, et al. “Global Cancer Statistics 2022: GLOBOCAN Estimates.” CA: A Cancer Journal for Clinicians, 2024.
14. Gnanapragasam, Vincent J., et al. “Urinary Symptoms and Prostate Cancer—The Misconception That May Be Preventing Earlier Presentation and Better Survival Outcomes.” BMC Medicine, 2022.
15. Stephan, Carsten, et al. “Non–Prostate Cancer-Related Factors That Influence Serum Prostate-Specific Antigen.” The Prostate, 2026.
16. Piñeros, Marion, et al. “An Updated Profile of the Cancer Burden, Patterns and Trends in Latin America and the Caribbean.” The Lancet Regional Health – Americas, 2022.